Compare TLS & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | STRO |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 85.0M |
| IPO Year | 2020 | 2018 |
| Metric | TLS | STRO |
|---|---|---|
| Price | $5.16 | $10.75 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | $7.75 | ★ $18.29 |
| AVG Volume (30 Days) | ★ 1.0M | 122.9K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $144,400,000.00 | $105,646,000.00 |
| Revenue This Year | $52.27 | $63.08 |
| Revenue Next Year | $20.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.44 | N/A |
| 52 Week Low | $1.83 | $5.23 |
| 52 Week High | $8.36 | $21.50 |
| Indicator | TLS | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 81.15 |
| Support Level | $5.05 | $8.49 |
| Resistance Level | $5.85 | $11.09 |
| Average True Range (ATR) | 0.34 | 0.83 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 13.30 | 89.41 |
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.